Zimmer Biomet Holdings, Inc. (ZBH)

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Symbol
ZBH
Exchange
NYSE
Sector
Healthcare
Industry
Medical Devices
Market cap
$16.97B
52 week range
79.12 - 106.88

Valuation

Share price
$88.29 (close of 2026-10-02)
P/E (TTM)
21.43x
Price to book
1.34x
Price to free cash flow
11.14x
Enterprise value
$24.04B
Book value per share
$65.73

Price performance

PeriodChange
1 day+0.26%
5 days-3.02%
1 month-11.27%
3 months+0.94%
6 months-2.86%
Year to date-1.81%
1 year-10.97%
3 years-20.76%
5 years-39.16%
10 years-30.06%
All time+205.61%

Members of Congress who disclosed ZBH trades

Robert Bresnahan · Alan Armstrong · Julie Johnson

Super investors holding ZBH

Dodge & Cox (Dodge & Cox Funds) · Bill Nygren (Harris Associates LP) · Ken Griffin (Citadel) · Harry Burn (Sound Shore Management) · Sarah Ketterer (Causeway Capital Management LLC) · Robert Olstein (Olstein Capital Management) · Hillman Capital (Hillman Capital Management, Inc) · Ray Dalio (Bridgewater Associates) · Mairs & Power (Mairs & Power Inc) · John Rogers (Ariel Investments LLC)

Profitability and growth

Return on equity
5.55%
Return on invested capital
4.95%
Return on assets
3.05%
Return on capital employed
5.35%
Gross margin
69.71%
Net margin
8.57%
EBITDA margin
26.63%
Revenue growth
7.20%
Net income growth
-21.98%
Free cash flow growth
13.66%

Cash flow and balance sheet

Free cash flow yield (TTM)
8.98%
Current ratio
1.69x
Net debt to EBITDA
3.03x

Latest reported year

Period end
2025-12-31
Fiscal year
2025
Revenue
$8.23B
Cost of revenue
$2.49B
Gross profit
$5.74B
EBITDA
$2.19B
Net income
$705.10M
Earnings per share
$3.56
Shares outstanding
198.00M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$8.23B$5.74B$705.10M$3.56
2024-12-31$7.68B$5.49B$903.80M$4.45
2023-12-31$7.39B$5.31B$1.02B$4.91
2022-12-31$6.94B$4.92B$231.40M$1.10
2021-12-31$6.83B$4.87B$401.60M$1.93
2020-12-31$6.13B$4.30B-$138.90M$-0.67
2019-12-31$7.98B$5.73B$1.13B$5.52
2018-12-31$7.93B$5.66B-$379.20M$-1.86
2017-12-31$7.80B$5.67B$1.81B$8.98
2016-12-31$7.67B$5.29B$305.90M$1.53

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3169.71%8.57%5.55%4.95%
2024-12-3171.46%11.77%7.24%6.36%
2023-12-3171.82%13.85%8.20%6.93%
2022-12-3170.90%3.33%1.92%3.37%
2021-12-3171.29%5.88%3.17%4.12%
2020-12-3170.23%-2.27%-1.14%0.42%
2019-12-3171.78%14.18%9.13%5.61%
2018-12-3171.36%-4.78%-3.36%0.08%
2017-12-3172.67%23.24%15.46%3.74%
2016-12-3168.94%3.99%3.16%3.58%

Cash and debt by year

Period endCashDebt
2025-12-31$591.90M$6.93B
2024-12-31$525.50M$5.34B
2023-12-31$415.80M$4.87B
2022-12-31$375.70M$5.15B
2021-12-31$378.10M$5.46B
2020-12-31$802.10M$7.63B
2019-12-31$617.90M$6.72B
2018-12-31$542.80M$8.41B
2017-12-31$524.40M$8.92B
2016-12-31$634.10M$10.67B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$1.47B$90.20M
2024-12-31$1.30B$101.00M
2023-12-31$1.29B$99.80M
2022-12-31$1.17B$105.00M
2021-12-31$1.36B$76.00M
2020-12-31$1.09B$73.80M
2019-12-31$1.38B$84.30M
2018-12-31$1.58B$65.50M
2017-12-31$1.43B$53.70M
2016-12-31$1.45B$57.30M

Dividend history

Most recent payment
2026-09-30
Paid in the last twelve months
$0.96
Payment dateDividend per share
2026-09-30$0.24
2026-06-25$0.24
2026-03-31$0.24
2025-12-30$0.24
2025-09-30$0.24
2025-06-26$0.24
2025-03-31$0.24
2024-12-30$0.24

Investor relations

Next earnings report

Next confirmed report
2026-11-04
Consensus EPS estimate
$1.89

Past earnings dates

ReportedFiscal periodEPS estimate
2026-08-05Jun/2026$2.01
2026-04-28Mar/2026$1.86
2026-02-10Dec/2025$2.38
2025-11-05Sep/2025$1.88
2025-08-07Jun/2025$1.98
2025-05-05Mar/2025$1.76
2025-02-06Dec/2024$2.30
2024-10-30Sep/2024$1.75

Filings and sources

Company website
zimmerbiomet.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Globus Medical Inc (GMED) · STERIS plc (STE) · Insulet Corp (PODD) · GE HealthCare Technologies Inc. (GEHC) · Dexcom Inc (DXCM) · Edwards Lifesciences Corp (EW) · McKesson Corp (MCK) · Cencora, Inc. (COR)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades